Last reviewed · How we verify

Poteligeo — Competitive Intelligence Brief

Poteligeo (Poteligeo) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed C-C chemokine receptor type 4 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Poteligeo (Poteligeo) — Kyowa Kirin Pharmaceutical Development Ltd.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Poteligeo TARGET Poteligeo Kyowa Kirin Pharmaceutical Development Ltd marketed C-C chemokine receptor type 4
Poteligeo MOGAMULIZUMAB Kyowa Kirin marketed Chemokine Receptor Type 4 Interaction [EPC] C-C chemokine receptor type 4 2018-01-01
MK-4280A MK-4280A Merck Sharp & Dohme LLC phase 3 CCR4 antagonist CCR4 (C-C chemokine receptor type 4)
MK-4280 MK-4280 Merck Sharp & Dohme LLC phase 3 CCR4 antagonist CCR4 (C-C chemokine receptor type 4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Poteligeo — Competitive Intelligence Brief. https://druglandscape.com/ci/poteligeo. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: